Foundayo Receives FDA Approval and Launches Nationwide
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: PRnewswire
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and became available through LillyDirect® and telehealth providers on April 9, marking a significant advancement in the weight loss market.
- Pricing and Accessibility: Foundayo is priced at $149 per month for self-pay patients, while eligible commercially insured patients can pay as little as $25 per month with a savings card, demonstrating Lilly's commitment to reducing patient burden and expanding drug accessibility.
- Clinical Trial Results: In the ATTAIN-1 clinical trial, patients on the highest dose lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, indicating a significant advantage in weight loss efficacy that could enhance market acceptance.
- Health Risks and Side Effects: Foundayo may cause serious side effects, including thyroid tumors, requiring patients to be vigilant for symptoms; nevertheless, the drug's effectiveness and convenience continue to attract many seeking weight loss solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 931.090
Low
950.00
Averages
1192
High
1500
Current: 931.090
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Foundayo Receives FDA Approval and Launches Nationwide
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and became available through LillyDirect® and telehealth providers on April 9, marking a significant advancement in the weight loss market.
- Pricing and Accessibility: Foundayo is priced at $149 per month for self-pay patients, while eligible commercially insured patients can pay as little as $25 per month with a savings card, demonstrating Lilly's commitment to reducing patient burden and expanding drug accessibility.
- Clinical Trial Results: In the ATTAIN-1 clinical trial, patients on the highest dose lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, indicating a significant advantage in weight loss efficacy that could enhance market acceptance.
- Health Risks and Side Effects: Foundayo may cause serious side effects, including thyroid tumors, requiring patients to be vigilant for symptoms; nevertheless, the drug's effectiveness and convenience continue to attract many seeking weight loss solutions.
See More
Eli Lilly Launches Foundayo Weight Loss Pill in U.S. Pharmacies
- Product Launch: Eli Lilly announced that its newly approved weight loss pill Foundayo (orforglipron) is now available in U.S. retail pharmacies, intensifying competition with Novo Nordisk, which launched its Wegovy pill earlier this year.
- Intensified Market Competition: Priced at $149 for a monthly supply for cash-paying customers, Foundayo's broader availability is expected to further escalate the competition in the oral weight loss drug market against Novo Nordisk's Wegovy, which has already gained traction since its launch.
- Expanded Prescription Channels: Following FDA approval earlier this month, Lilly quickly began accepting Foundayo prescriptions through its direct-to-consumer site, LillyDirect, and has now expanded shipments to nationwide retail pharmacies, demonstrating rapid market penetration.
- Diverse Patient Options: Novo Nordisk's Wegovy has introduced a subscription program allowing cash-paying patients to receive discounted medications, and the launch of Lilly's new drug will provide patients with more options, potentially impacting market share dynamics.
See More
GLP-1 Drugs Drive Growth in U.S. Apparel Spending
- Surge in Apparel Demand: Approximately 80% of GLP-1 users anticipate needing new clothing due to size changes, with a Circana survey revealing that 55% of active users have already purchased new items, indicating a fresh wave of consumer spending in the apparel market.
- Significant Market Potential: Bernstein estimates that GLP-1 users could purchase between 150 million and 700 million apparel items due to weight loss, translating to an additional $13 billion in annual spending in the U.S. apparel sector, highlighting robust market demand.
- Brands Adapting to Change: Retailers like Stitch Fix have launched targeted marketing campaigns for weight loss users, with client mentions of weight loss requests tripling over the past two years, demonstrating brands' proactive adaptation to this emerging trend.
- Shift in Consumer Behavior: An increasing number of consumers are opting for more affordable clothing during their weight loss journey, with Destination XL's CEO noting that about 25% of their customers are using GLP-1 drugs, leading to a preference for cost-effective options.
See More
India's Low-Cost Drug Surge Disrupts Market Dynamics
- Market Share Shift: In India, Novo Nordisk's semaglutide has increased its share in the GLP-1 market from 25% to 33% in March, indicating that low-cost generics are rapidly reshaping market dynamics and undermining Eli Lilly's competitive edge.
- Sales Decline: Eli Lilly's Mounjaro saw its sales drop to 1.14 billion rupees ($12.3 million) in March from 1.35 billion rupees the previous month, highlighting the direct impact of generics on branded drug revenues.
- Intensifying Competition: Torrent Pharmaceuticals has emerged as the largest local competitor for semaglutide with an 8% market share, while Novo retains a dominant 70%, suggesting that the entry of generics will further intensify market competition.
- Patent Expiry Impact: As global patents expire, the Indian market serves as a critical case study for observing how generics can erode the dominance of branded drugs, with future price wars likely to have profound implications for Eli Lilly's market strategy.
See More
Indian Textile Industry Faces New Challenges Amid Iran War
- Export Decline: India's textile exports from April 2025 to February 2026 totaled $29.5 billion, a slight drop from $29.8 billion the previous year, indicating the fragility of recovery in an industry aiming for $100 billion in exports by 2030.
- Rising Costs: The Iran war has driven raw material and packaging costs up, with polyester prices increasing over 40% since the conflict began, complicating companies' ability to pass costs onto customers and impacting production and profitability.
- Weak Demand: Although tariff relief from the U.S. provided temporary respite, industry leaders warn that a prolonged war could dampen U.S. consumer demand, leading to declining sales and rising inventories, posing significant challenges for retailers.
- Production Cuts: Companies like Filatex have already reduced production by 25% and are awaiting demand recovery, with widespread concerns that failure to pass on costs could lead to larger-scale production cuts, further affecting employment and economic growth.
See More
NXERA PHARMA CO LTD - POTENTIAL TO RECEIVE UP TO $694 MILLION IN MILESTONES AND TIERED ROYALTIES FROM LILLY AGREEMENT
Company Announcement: NERAPHARMA COLTD has announced eligibility for up to $694 million in milestone payments.
Partnership Details: The agreement involves collaboration with Royal Ties under the Lilly agreement.
See More
Foundayo Receives FDA Approval and Launches Nationwide
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and became available through LillyDirect® and telehealth providers on April 9, marking a significant advancement in the weight loss market.
- Pricing and Accessibility: Foundayo is priced at $149 per month for self-pay patients, while eligible commercially insured patients can pay as little as $25 per month with a savings card, demonstrating Lilly's commitment to reducing patient burden and expanding drug accessibility.
- Clinical Trial Results: In the ATTAIN-1 clinical trial, patients on the highest dose lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, indicating a significant advantage in weight loss efficacy that could enhance market acceptance.
- Health Risks and Side Effects: Foundayo may cause serious side effects, including thyroid tumors, requiring patients to be vigilant for symptoms; nevertheless, the drug's effectiveness and convenience continue to attract many seeking weight loss solutions.
See More
Eli Lilly Launches Foundayo Weight Loss Pill in U.S. Pharmacies
- Product Launch: Eli Lilly announced that its newly approved weight loss pill Foundayo (orforglipron) is now available in U.S. retail pharmacies, intensifying competition with Novo Nordisk, which launched its Wegovy pill earlier this year.
- Intensified Market Competition: Priced at $149 for a monthly supply for cash-paying customers, Foundayo's broader availability is expected to further escalate the competition in the oral weight loss drug market against Novo Nordisk's Wegovy, which has already gained traction since its launch.
- Expanded Prescription Channels: Following FDA approval earlier this month, Lilly quickly began accepting Foundayo prescriptions through its direct-to-consumer site, LillyDirect, and has now expanded shipments to nationwide retail pharmacies, demonstrating rapid market penetration.
- Diverse Patient Options: Novo Nordisk's Wegovy has introduced a subscription program allowing cash-paying patients to receive discounted medications, and the launch of Lilly's new drug will provide patients with more options, potentially impacting market share dynamics.
See More
GLP-1 Drugs Drive Growth in U.S. Apparel Spending
- Surge in Apparel Demand: Approximately 80% of GLP-1 users anticipate needing new clothing due to size changes, with a Circana survey revealing that 55% of active users have already purchased new items, indicating a fresh wave of consumer spending in the apparel market.
- Significant Market Potential: Bernstein estimates that GLP-1 users could purchase between 150 million and 700 million apparel items due to weight loss, translating to an additional $13 billion in annual spending in the U.S. apparel sector, highlighting robust market demand.
- Brands Adapting to Change: Retailers like Stitch Fix have launched targeted marketing campaigns for weight loss users, with client mentions of weight loss requests tripling over the past two years, demonstrating brands' proactive adaptation to this emerging trend.
- Shift in Consumer Behavior: An increasing number of consumers are opting for more affordable clothing during their weight loss journey, with Destination XL's CEO noting that about 25% of their customers are using GLP-1 drugs, leading to a preference for cost-effective options.
See More
India's Low-Cost Drug Surge Disrupts Market Dynamics
- Market Share Shift: In India, Novo Nordisk's semaglutide has increased its share in the GLP-1 market from 25% to 33% in March, indicating that low-cost generics are rapidly reshaping market dynamics and undermining Eli Lilly's competitive edge.
- Sales Decline: Eli Lilly's Mounjaro saw its sales drop to 1.14 billion rupees ($12.3 million) in March from 1.35 billion rupees the previous month, highlighting the direct impact of generics on branded drug revenues.
- Intensifying Competition: Torrent Pharmaceuticals has emerged as the largest local competitor for semaglutide with an 8% market share, while Novo retains a dominant 70%, suggesting that the entry of generics will further intensify market competition.
- Patent Expiry Impact: As global patents expire, the Indian market serves as a critical case study for observing how generics can erode the dominance of branded drugs, with future price wars likely to have profound implications for Eli Lilly's market strategy.
See More
Indian Textile Industry Faces New Challenges Amid Iran War
- Export Decline: India's textile exports from April 2025 to February 2026 totaled $29.5 billion, a slight drop from $29.8 billion the previous year, indicating the fragility of recovery in an industry aiming for $100 billion in exports by 2030.
- Rising Costs: The Iran war has driven raw material and packaging costs up, with polyester prices increasing over 40% since the conflict began, complicating companies' ability to pass costs onto customers and impacting production and profitability.
- Weak Demand: Although tariff relief from the U.S. provided temporary respite, industry leaders warn that a prolonged war could dampen U.S. consumer demand, leading to declining sales and rising inventories, posing significant challenges for retailers.
- Production Cuts: Companies like Filatex have already reduced production by 25% and are awaiting demand recovery, with widespread concerns that failure to pass on costs could lead to larger-scale production cuts, further affecting employment and economic growth.
See More
NXERA PHARMA CO LTD - POTENTIAL TO RECEIVE UP TO $694 MILLION IN MILESTONES AND TIERED ROYALTIES FROM LILLY AGREEMENT
Company Announcement: NERAPHARMA COLTD has announced eligibility for up to $694 million in milestone payments.
Partnership Details: The agreement involves collaboration with Royal Ties under the Lilly agreement.
See More
